LEK-8829

LEK-8829 is an **ergoline derivative** with a unique pharmacological profile, acting as a **dopamine D1 receptor agonist** and a **dopamine D2 receptor antagonist**, while also exhibiting high affinity for **serotonin 5-HT2** and **5-HT1A receptors**. It is considered a putative atypical antipsychotic with potential applications in the treatment of **psychotic disorders**, including drug-induced psychosis in Parkinson’s disease, and as a candidate medication for **cocaine craving in addiction**. LEK-8829 demonstrates mesolimbic selectivity, which may contribute to a **lower propensity for extrapyramidal side effects**, sedation, anticholinergic, and hypotensive side effects compared to classic antipsychotics. It has been primarily developed as an experimental tool for investigating D1:D2 receptor interactions and exhibits beneficial effects in both dopaminergic and serotonergic systems[1][3][5][7].

Other names

9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8β-aminomethylergoline bimaleate